Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WOCKPHARMA.NS
HoldPremium GrowerWockhardt Limited · Healthcare · India · $3.8B · Avg Vol: $23M/d
54
StockRankGet insider-trade alerts
Q
56
V
13
M
79
P/E (TTM)
89.5x
ROE
4.3%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 26.5B | 27.9B | 29.1B | 33.2B | 7.8% | 36.7B |
| EPS (INR) | -38.79 | -32.05 | -3.02 | 13.12 | — | 25.22 |
| Shares | 144.1M | 153.4M | 162.5M | 162.5M | +12.8% | 162.5M |
| Debt | 21.8B | 23.6B | 20.2B | 22.3B | 0.7% | 22.4B |
| Equity | 33.5B | 33.6B | 43.5B | 49.4B | 13.8% | — |
| Op CF | 1.5B | 2.2B | -220.0M | 3.9B | 36.6% | 3.9B |
| Inv CF | -1.3B | -1.4B | -7.8B | -2.4B | — | — |
| Fin CF | -3.1B | 3.3B | 4.1B | -540.0M | — | — |
Loading 1Y...
PRICE (1Y)+18.1%
SMA 50SMA 200
Close
$23.56
RSI (14)
79.5
52W High
$25.38
From 52W High
0.9%
SCORE BREAKDOWN
Quality
56
ROIC
6.4%59.5
ROE
4.3%53.9
GP/Assets
27.6%59.4
Op. Margin
14.3%73.3
FCF/Assets
0.3%46.7
Piotroski
894.2
Int. Cover
2.1x42.9
D/E Ratio
0.42x32.6
Current Ratio
1.66x31.1
Value
13
P/E (TTM)
89.5x10.4
EV/EBITDA
50.9x11.4
P/FCF
1401.9x1.3
P/B
7.4x17.4
P/S
10.0x25.6
Div Yield
—N/A
Momentum
79
52W High %
93%89.3
RS 6M
76%94.7
SMA 50/200
1.21x88.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$3.8B
P/E (Forward)
—
Gross Margin
65.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WOCKPHARMA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WOCKPHARMA.NS | Wockhardt Limited(you) | $3.8B | 54 | Hold |
| PPLPHARMA.NS | Piramal Pharma Limited | $3.2B | 58 | Hold |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 56 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| DRREDDY.NS | Dr. Reddy's Laboratories Limited | $10.1B | 50 | Hold |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%